Developer docs
API playgroundTry for free, no card

Search company profiles

Scripps Translational Science Institute

Full company profile

uuid0003gol

Namestring
Scripps Translational Science Institute
Websiteurl
stsiweb.org
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Scripps Translational Science Institute (STSI) is a privately held translational genomics research organization founded in 2006 and headquartered in La Jolla, California. Its stated mission is to translate advances in genomics into new diagnostics and treatments, operating at the intersection of academic research and clinical application. The institute is affiliated with Scripps Research and is led by founder and director Eric Topol, a prominent figure in genomics and digital medicine, alongside senior scientific leadership including the Director of Genomics and Genome Informatics and the Director of Clinical Research / Liver Disease Center.

The organization operates with a headcount of 11-50 employees, consistent with a focused research institute rather than a scaled commercial enterprise. Its core activity is translational genomics research, implying the integration of large-scale genomic data, clinical phenotyping, and bioinformatics to develop diagnostic and therapeutic candidates. The institute received a $34 million award from the National Institutes of Health in May 2018, indicating its capacity to attract large-scale federal research funding — a primary revenue mechanism for translational research institutes.

Business model mechanics are not explicitly disclosed, but the institute appears to be primarily grant-funded through federal sources (notably NIH) rather than driven by commercial product revenue, licensing, or fee-for-service income at material scale. The 'for_profit' legal designation is notable given its research-institute operating posture; no customer logos, pricing models, commercial product lines, or GTM motions are disclosed in the available data, reinforcing that STSI functions closer to a research entity than a commercial operating company. Geographic footprint is concentrated in La Jolla, with no disclosed international operations or commercial distribution channels.

Short descriptiontext

Scripps Translational Science Institute is a La Jolla-based research organization founded in 2006 that translates advances in genomics into new diagnostics and treatments, operating primarily on federal research funding with Eric Topol as founder and director.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLa Jolla, United States
HQ citystring
La Jolla
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
translational genomics research, genomic diagnostics development, precision medicine research, clinical genomics studies, biomedical research institute
Industry5 codes
1Translational Medicine & Biomarkers
CodeHLAIALAFPrimaryYes
2Molecular Diagnostics & Genomics Laboratories
CodeHLAFAMAEPrimaryNo
3Molecular Diagnostics (PCR/qPCR, NGS-based assays)
CodeHLAAALAAPrimaryNo
4Genomics & Molecular Diagnostics (Trial Support)
CodeHLAGAEADPrimaryNo
5Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
CodeHLAAALAOPrimaryNo
NAICS code4 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical and Diagnostic Laboratories62151
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Translational Genomics Research
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Scripps Translational Science Institute translates the latest advances in genomics into new diagnostics and treatments. The institute conducts translational genomics research, houses a Liver Disease Center with associated clinical research, and operates a genomics and genome informatics program that bridges laboratory discoveries with clinical applications.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1Translational Genomics Research Programs
CategoryTranslational Genomics Research
2Liver Disease Center Clinical Research
3Genomics and Genome Informatics Services
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Translational Genomics Research Institute (TGen)
TypeDirect peer
Description

Non-profit translational genomics institute operating in a near-identical model: translating genomic discoveries into clinical diagnostics and therapeutics, with comparable wet-lab and computational genomics teams.

2Regeneron Genetics Center
TypeBroad incumbent
Description

Large-scale genomics-to-drug-discovery engine embedded within Regeneron; comparable in translating human genetics into therapeutic and diagnostic insights, but with vastly greater resources and a commercial sponsor.

3Human Longevity Inc.
TypeEmerging player
Description

Genomics-driven precision health company combining whole-genome sequencing with AI to deliver diagnostics and risk predictions—directly overlaps STSI's translational genomics and AI-enabled diagnostics positioning.

4Foundation Medicine
TypeBroad incumbent
Description

Established leader in NGS-based molecular diagnostics, especially in oncology. Represents the scaled commercial endpoint that translational genomics institutes like STSI aspire to reach.

5Tempus Labs
TypeBroad incumbent
Description

AI-enabled precision medicine company combining multi-modal data, including genomics, for clinical decision support; competes for the same translational genomics-to-diagnostics value chain.

6Color
TypeEmerging player
Description

Population-scale genomics and preventive health company offering clinically validated genetic testing; comparable in translating genomics into deployable diagnostic products at scale.

7Helix
TypeEmerging player
Description

Genomics platform company focused on population health and clinical-grade sequencing; overlaps with STSI's translational focus on turning NGS data into actionable diagnostic outputs.

8Broad Institute
TypeDirect peer
Description

Leading genomics and biomedical research institute with significant translational programs in genomic medicine and diagnostics; closest analog in terms of translational science ambition and scale.

9New York Genome Center
TypeDirect peer
Description

Independent genomics research institute combining large-scale sequencing, computational genomics, and clinical collaboration—mirrors STSI's translational research operating model.

10BC Platforms
TypeOthers
Description

Genomics data and translational research infrastructure provider; comparable in serving the genomics-to-clinic workflow, but positioned as an enabling technology vendor rather than a clinical diagnostic.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scripps Translational Science Institute

Translational Genomics Researchstsiweb.org

Scripps Translational Science Institute is a La Jolla-based research organization founded in 2006 that translates advances in genomics into new diagnostics and treatments, operating primarily on federal research funding with Eric Topol as founder and director.

What Scripps Translational Science Institute does

Scripps Translational Science Institute (STSI) is a privately held translational genomics research organization founded in 2006 and headquartered in La Jolla, California. Its stated mission is to translate advances in genomics into new diagnostics and treatments, operating at the intersection of academic research and clinical application. The institute is affiliated with Scripps Research and is led by founder and director Eric Topol, a prominent figure in genomics and digital medicine, alongside senior scientific leadership including the Director of Genomics and Genome Informatics and the Director of Clinical Research / Liver Disease Center.

The organization operates with a headcount of 11-50 employees, consistent with a focused research institute rather than a scaled commercial enterprise. Its core activity is translational genomics research, implying the integration of large-scale genomic data, clinical phenotyping, and bioinformatics to develop diagnostic and therapeutic candidates. The institute received a $34 million award from the National Institutes of Health in May 2018, indicating its capacity to attract large-scale federal research funding — a primary revenue mechanism for translational research institutes.

Business model mechanics are not explicitly disclosed, but the institute appears to be primarily grant-funded through federal sources (notably NIH) rather than driven by commercial product revenue, licensing, or fee-for-service income at material scale. The 'for_profit' legal designation is notable given its research-institute operating posture; no customer logos, pricing models, commercial product lines, or GTM motions are disclosed in the available data, reinforcing that STSI functions closer to a research entity than a commercial operating company. Geographic footprint is concentrated in La Jolla, with no disclosed international operations or commercial distribution channels.

Scripps Translational Science Institute firmographics

Firmographics
Name
Scripps Translational Science Institute
Website
https://stsiweb.org
Company type
Private
Founded year
2006
Headcount range
11–50 employees
Short description
Scripps Translational Science Institute is a La Jolla-based research organization founded in 2006 that translates advances in genomics into new diagnostics and treatments, operating primarily on federal research funding with Eric Topol as founder and director.
Ownership category
akta.pro rank

Scripps Translational Science Institute industry classification

Industry
Product category
Translational Genomics Research
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry
Translational Medicine & Biomarkers (HLAIALAF)
akta.pro secondary industries
Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

  • Translational genomics research
  • Genomic diagnostics development
  • Precision medicine research
  • Clinical genomics studies
  • Biomedical research institute

Where Scripps Translational Science Institute is headquartered

Location

Headquarters

HQ city
La Jolla
HQ country
United States
HQ region
North America

Markets served

Scripps Translational Science Institute business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Scripps Translational Science Institute product offering

Product offering

Core offering

Scripps Translational Science Institute translates the latest advances in genomics into new diagnostics and treatments. The institute conducts translational genomics research, houses a Liver Disease Center with associated clinical research, and operates a genomics and genome informatics program that bridges laboratory discoveries with clinical applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Translational Genomics Research Programs
  • Liver Disease Center Clinical Research
  • Genomics and Genome Informatics Services

Companies that use Scripps Translational Science Institute

Customer profile

Ideal customer profiles1 record

Scripps Translational Science Institute technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Scripps Translational Science Institute partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

Scripps Translational Science Institute competitors and assessment

Company assessment

Direct peers

  • Translational Genomics Research Institute (TGen): Non-profit translational genomics institute operating in a near-identical model: translating genomic discoveries into clinical diagnostics and therapeutics, with comparable wet-lab and computational genomics teams.
  • Broad Institute: Leading genomics and biomedical research institute with significant translational programs in genomic medicine and diagnostics; closest analog in terms of translational science ambition and scale.
  • New York Genome Center: Independent genomics research institute combining large-scale sequencing, computational genomics, and clinical collaboration—mirrors STSI's translational research operating model.

Broad incumbents

  • Regeneron Genetics Center: Large-scale genomics-to-drug-discovery engine embedded within Regeneron; comparable in translating human genetics into therapeutic and diagnostic insights, but with vastly greater resources and a commercial sponsor.
  • Foundation Medicine: Established leader in NGS-based molecular diagnostics, especially in oncology. Represents the scaled commercial endpoint that translational genomics institutes like STSI aspire to reach.
  • Tempus Labs: AI-enabled precision medicine company combining multi-modal data, including genomics, for clinical decision support; competes for the same translational genomics-to-diagnostics value chain.

Emerging players

  • Human Longevity Inc. Genomics-driven precision health company combining whole-genome sequencing with AI to deliver diagnostics and risk predictions—directly overlaps STSI's translational genomics and AI-enabled diagnostics positioning.
  • Color: Population-scale genomics and preventive health company offering clinically validated genetic testing; comparable in translating genomics into deployable diagnostic products at scale.
  • Helix: Genomics platform company focused on population health and clinical-grade sequencing; overlaps with STSI's translational focus on turning NGS data into actionable diagnostic outputs.

Others

  • BC Platforms: Genomics data and translational research infrastructure provider; comparable in serving the genomics-to-clinic workflow, but positioned as an enabling technology vendor rather than a clinical diagnostic.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Scripps Translational Science Institute social profiles

Digital presence

Scripps Translational Science Institute financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scripps Translational Science Institute leadership team

Management profile

Number of profiles

Profiles3 records

Scripps Translational Science Institute funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scripps Translational Science Institute M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scripps Translational Science Institute

What does Scripps Translational Science Institute do?

Scripps Translational Science Institute translates the latest advances in genomics into new diagnostics and treatments. The institute conducts translational genomics research, houses a Liver Disease Center with associated clinical research, and operates a genomics and genome informatics program that bridges laboratory discoveries with clinical applications.

When was Scripps Translational Science Institute founded?

Scripps Translational Science Institute was founded in 2006. It employs 11 to 50 people.

Where is Scripps Translational Science Institute based?

Scripps Translational Science Institute is headquartered in La Jolla, United States, in the North America region.

Who are Scripps Translational Science Institute's main competitors?

Direct peers on record are Translational Genomics Research Institute (TGen), Broad Institute and New York Genome Center. Broad incumbents are Regeneron Genetics Center, Foundation Medicine and Tempus Labs. Emerging players are Human Longevity Inc., Color and Helix. BC Platforms is listed as an others.

Does Scripps Translational Science Institute have an API?

No public API is recorded for Scripps Translational Science Institute.

What industry is Scripps Translational Science Institute in?

Scripps Translational Science Institute's product category is Translational Genomics Research. Its primary akta.pro industry code is HLAIALAF, Translational Medicine & Biomarkers, with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WsjA Doctor’s Science-Backed Formula for Aging BetterDr. Eric Topol and colleagues at Scripps Research Translational Institute enrolled healthy people aged 85 and older in a study to test whether genes explain longevity. They sequenced and analyzed the participants' DNA to investigate genetic factors in aging.WsjA Doctor’s Science-Backed Formula for Aging BetterDr. Eric Topol and colleagues at Scripps Research Translational Institute sequenced DNA of healthy people aged 85 and older to test whether genes explain longevity. The study, published in the journal Aging, found that genetic factors do not fully account for the health of the oldest-old.PR NewswireNational Institutes of Health All of Us Research Program Mobile Tour Visits Houston, TXThe National Institutes of Health's All of Us Journey, a traveling educational exhibit promoting the All of Us Research Program, will visit Houston from April 30 to May 3, 2024, hosted by 50Forward and Baylor College of Medicine. The program aims to recruit at least one million participants reflecting the diversity of the United States to advance health research. The Journey is managed by Montage Marketing Group in collaboration with Scripps Research Translational Institute, with funding from NIH award OT2OD035580.American Medical AssociationEducation & resources in genetics & personalized medicineThe American Medical Association (AMA) has partnered with Scripps Translational Science Institute and The Jackson Laboratory to develop 'Precision Medicine for Your Practice,' a series of free online educational modules on genomics and precision medicine. These modules, released throughout 2016 and 2017, cover topics such as carrier screening, cancer panels, and pharmacogenomics, and offer CME credit via the AMA EdHub.PR NewswireElektra Labs and the Scripps Research Translational Institute Partner to Incorporate Scripps' Digital Health Library into the Elektra Labs Atlas PlatformElektra Labs and Scripps Research Translational Institute announced the integration of the Digital Health Library into Elektra's Atlas platform. This partnership combines a crowd-sourced collection of digital health technologies with a searchable remote monitoring product catalog to help clinicians and researchers evaluate connected sensor technologies. The move aims to facilitate access to evidence-based technologies and support personalized healthcare through real-time health monitoring.PR NewswireAmerican College Health Association and Scripps Research Translational Institute Partner to Bring the NIH All of Us Research Program to College CampusesThe American College Health Association and Scripps Research Translational Institute have announced a partnership to bring the NIH All of Us Research Program to five college campuses this academic year as a pilot program. The All of Us program aims to build the largest, most diverse health resource by collecting health information from one million or more participants to enable research into how genetics, lifestyle, and environmental factors impact health outcomes. The five participating schools include Albion College, California State Polytechnic University-Pomona, Florida International University, Texas Southern University, and University of Louisville, which will use student engagement associates to educate peers about the program.PR NewswireLet's Celebrate Hispanic Heritage Month with "All of Us!"Five San Diego-based health organizations (National Alliance for Hispanic Health, San Diego Blood Bank, San Ysidro Health Center, Scripps Research Translational Institute, and UC San Diego Health) will host a Spanish-language Facebook Live event on October 5, 2018, to promote the All of Us Research Program during Hispanic Heritage Month. The All of Us Research Program is a national initiative seeking 1 million volunteers to share health and lifestyle data to accelerate precision medicine research. Additional community health events are scheduled throughout Hispanic Heritage Month in the San Diego area, including cancer screenings and wellness walks.PR Newswire¡Celebremos el Mes de la Herencia Hispana con "All of Us"!The National Alliance for Hispanic Health, San Diego Blood Bank, San Ysidro Health Center, Scripps Research Translational Institute, and UC San Diego Health are co-hosting a Facebook Live event in Spanish on October 5, 2018, to discuss the All of Us precision medicine research program during Hispanic Heritage Month. The All of Us program aims to enroll 1 million volunteers to accelerate health research and advance precision medicine, with a focus on populations historically underrepresented in scientific research. The hosting organizations will also participate in various community health events throughout September and October in the San Diego area.PR NewswireNew ResearchKit App from The Scripps Research Institute Looks at How Genetic Risk Influences Heart Health DecisionsScientists at the Scripps Translational Science Institute and The Scripps Research Institute have launched a smartphone app research study called MyGeneRank, built on Apple's ResearchKit framework, to investigate how receiving personal genetic risk information for coronary artery disease influences health decisions. The app connects with 23andMe genetic data to calculate and return estimated genetic risk scores and 10-year absolute risk estimates, using surveys and Apple HealthKit data to assess whether this information guides lifestyle modifications and statin medication use. The researchers plan to expand the app to other diseases, support the Android operating system, and integrate additional commercial personal genetic data platforms.PR NewswireWebMD and Scripps Translational Science Institute Launch Study to Understand Factors That Contribute to Healthy PregnanciesWebMD and Scripps Translational Science Institute announced on March 20, 2017 the launch of the Healthy Pregnancy Study, a research initiative designed to improve understanding of factors contributing to healthy pregnancies and positive pregnancy outcomes. The study will leverage WebMD's newly redesigned Pregnancy app for iPhone, incorporating Apple's ResearchKit software framework to enable participants to eConsent, answer survey questions anonymously, and share connected device data with researchers for analysis. The collaboration aims to help scientists and healthcare professionals gather important medical insights from expectant mothers who participate through the app.